HANNOVER, Germany, October 18, 2021 / B3C newswire / -- Implandata Ophthalmic Products, a digital health eye care company with offices in Germany and San Diego, California has been selected as Top 12 Health Techpreneur at the Healthcare Innovation World Cup at Medica, the world’s largest medical trade fair. Out of more than 300 competitors, Implandata has been awarded as a leading breakthrough health care innovator and was invited to present its disruptive EYEMATE solution on Nov 15, 2021 at Medica Connected Health Care Forum.
Implandata’s proprietary EYEMATE system is the world’s only clinically-validated and CE marked product for remote glaucoma care. US FDA Breakthrough Device Designation was obtained earlier in 2021. The system empowers patients to self-measure critical disease parameters, and then automatically sends gathered information in real-time to their eye doctors. This information enables eye doctors to obtain timely information about therapy effectiveness and to remotely adjust treatment based on a patient’s current condition rather than make therapeutic adjustments based on only infrequent office visits.
For high resolution please click the image.
About Glaucoma – the leading cause of irreversible debilitating vision loss worldwide
Glaucoma is an age-related chronic eye disease, where elevated pressure in the eye causes irreversible damages to the optic nerve, leading to progressive loss of eyesight and potentially blindness. Current practice of seeing patients in 2-4 office visits per year is insufficient to prevent loss of eyesight for many patients, as disease status and eye pressure lowering therapy effectiveness between office visits are not known. Despite a wealth of treatment options, ineffective therapies and disease progression results in preventable loss of eyesight at a considerable number of patients.
About the EYEMATE™ System
EYEMATE is the first-of-its-kind CE-marked and clinically-validated system for continual, remote monitoring and management of glaucoma patients. Implandata’s proprietary biosensors and cloud-based, AI-system alerts patients and their eye doctor in of uncontrolled glaucoma real-time, enabling timely therapy adjustment to prevent vision loss.
About Implandata Ophthalmic Products
Implandata, based in Germany and the USA, is a digital health company dedicated to improving the life of millions of glaucoma patients. Breakthroughs in biosensors, telemetry and data analytics led to the EYEMATE system. The CE-marked EYEMATE system is in use at leading eye centers in Europe. Untouched huge market opportunities in North America and China will be approached in the very near future.
Contact
Implandata Ophthalmic Products
Max Ostermeier, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.implandata.com
Keywords: Humans: Awards and Prizes; Glaucoma; Vision Disorders; Intraocular Pressures; Pressure, Intraocular; Monitoring, Physiological; Eye Diseases; Disease Progression; Patient Monitoring; Digital Health; Telemedicine; Biosensors; Biosensing Techniques; AI, Deep Learning; Ophthalmology; Remote Monitoring; Telemedicine; Breakthrough Device Designation; FDA; CE Mark; NMPA; Germany; California
Published by B3C newswire